Analysis of physiological factors regulating oral absorption behaviors of drugs and its application to prediction of plasma concentration-time profile
药物口服吸收行为生理因素分析及其在血药浓度-时间曲线预测中的应用
基本信息
- 批准号:17590124
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2005
- 资助国家:日本
- 起止时间:2005 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
In order to predict the oral absorption behaviors of drugs subjected to metabolism and/or secretion in the intestinal mucosa, we focused on P-glycoprotein (P-pg) as a secretion mechanism, and Cyp3A as a metabolism mechanism, and tried to develop the quantitative evaluation systems which allow us to estimate the effects of P-gp and Cyp3A on the oral absorption behavior. With oral dosing of dexamethasone (DEX) at 25-100 mg/kg/day for 2 days, rats having P-gp and Cyp3A at higher levels were prepared. High expression of P-gp and Cyp3A were recognized by estimating the secretion of rhodamine 123 in isolated intestinal sheets and the generation of 6β-0H of testosterone in microsome, respectively. Furthermore, we developed a vascularly perfused intestine-liver preparation, which makes it possible to evaluate the absorption, secretion, metabolism in the small intestine and the metabolism in the liver at the same time. The absorption kinetics of quinidine was successfully evaluated with a vascu … More larly perfused intestine-liver preparation.On the other hand, many substrates for P-gp and/or Cyp3A are well known to be high lipophilic and poorly water-soluble. Therefore, we tried to predict the absorption behaviors of poorly water-soluble drugs after oral dosing as powders based on Gastrointestinal-Transit-Absorption model (GITA model). Griseofulvin, classified into Biopharmaceutics Classification System class II, was selected as a model compound. Dissolution process, assumed to obey the first-order kinetics, was incorporated into GITA model and the dissolution rate constants were determined by utilizing several existing media such as Japanese Pharmacopeia (JP) 1st solution, 2nd solution, fasted-state simulated intestinal fluids (FaSSIF) and fed-state simulated intestinal fluids (FeSSIF). However, simulated lines obtained with these dissolution rate constants were not in good agreement with the observed profile of plasma concentration of griseofulvin at all. Therefore, we developed a couple of new media, medium reflection in-vivo dissolution (MREVID) 1 and 2. Then, based on GITA model, the plasma concentration-time profile of griseofulvin after oral administration was predicted by utilizing the dissolution rate constants obtained with the new media. As a result, a simulation curve calculated by utilizing the dissolution rate constant obtained with MREVID 2 provided the best description of the observed line, which was good enough to predict Cmax and AUC although there was a little difference in Tmax between the observed and calculated values. Less
为了预测药物在肠粘膜中代谢和/或分泌后的口服吸收行为,我们以P-糖蛋白(P-pg)为分泌机制,以Cyp 3A为代谢机制,尝试建立定量评价系统,以评价P-gp和Cyp 3A对口服吸收行为的影响。通过口服给予25-100 mg/kg/天的地塞米松(DEX)2天,制备具有较高水平的P-gp和Cyp 3A的大鼠。P-gp和Cyp 3A的高表达分别通过测定离体肠片中罗丹明123的分泌和微粒体中睾酮的6β-OH的产生来确认。此外,我们还开发了一种血管灌注的小肠-肝脏制剂,这使得可以同时评价小肠中的吸收、分泌、代谢和肝脏中的代谢。用血管吸收动力学法研究了奎尼丁的吸收动力学 ...更多信息 另一方面,众所周知,P-gp和/或Cyp 3A的许多底物是高度亲脂性的和水溶性差的。因此,我们尝试基于胃肠道-转运-吸收模型(GITA模型)预测水溶性差的药物以粉末形式口服给药后的吸收行为。灰黄霉素,归类为生物药剂学分类系统II类,被选为模型化合物。将溶出过程假设为一级动力学,并将其纳入GITA模型,利用日本药典(JP)第1溶液、第2溶液、禁食状态模拟肠液(FaSSIF)和进食状态模拟肠液(FeSSIF)等几种现有介质测定溶出速率常数。然而,这些溶出速率常数得到的模拟线并不与灰黄霉素的血浆浓度的观察曲线在所有良好的协议。因此,我们开发了几种新介质,介质反射体内溶解(MREVID)1和2。基于GITA模型,利用新介质的溶出速率常数预测口服给药后灰黄霉素的血药浓度-时间曲线。因此,通过使用MREVID 2获得的溶出速率常数计算的模拟曲线提供了对观察到的线的最佳描述,其足以预测Cmax和AUC,尽管观察值和计算值之间的Tmax存在微小差异。少
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model:: Utilization of a more suitable medium for in-vitro dissolution study
- DOI:10.1016/j.jconrel.2007.03.002
- 发表时间:2007-06-01
- 期刊:
- 影响因子:10.8
- 作者:Fujioka, Yoshitsugu;Kadono, Keltaro;Kimura, Toshikiro
- 通讯作者:Kimura, Toshikiro
Pharmacokinetic analysis of in-vivo dissolution and absorption behavior of poorly water-soluble drugs after oral administration.
难溶性药物口服后体内溶出和吸收行为的药代动力学分析。
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Nagai;J.;et al.;Watanabe E et al.;Y.Fujioka
- 通讯作者:Y.Fujioka
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KIMURA Toshikiro其他文献
KIMURA Toshikiro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KIMURA Toshikiro', 18)}}的其他基金
Analysis of dissolution kinetics and first-pass elimination of orally administered drugs and its application to prediction of absorption behavior after oral administration
口服药物溶出动力学和首过消除分析及其在预测口服后吸收行为中的应用
- 批准号:
21590158 - 财政年份:2009
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of first-pass effect in small intestinal mucosa and its application to prediction of drug absorption behavior after oral administration
小肠黏膜首过效应分析及其在预测口服药物吸收行为中的应用
- 批准号:
19590144 - 财政年份:2007
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Drug Permeation Mechanism across Oral Mucosa Using Cultured Stratified Cell Layers
使用培养的分层细胞层分析药物在口腔粘膜的渗透机制
- 批准号:
15590131 - 财政年份:2003
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Carrier-Mediated Transport Systems in Drug Absorption from Oral Mucosa
口腔粘膜药物吸收中载体介导的转运系统分析
- 批准号:
10672041 - 财政年份:1998
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Experimental Analysis of Anomalous Pharmacokinetics in Disease State: Pharmacokinetics in Diabetes
疾病状态下异常药代动力学的实验分析:糖尿病的药代动力学
- 批准号:
63571097 - 财政年份:1988
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似国自然基金
基于深度学习的P-gp抑制剂虚拟筛选平台构建及抗肿瘤耐药机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
新型肿瘤微环境响应型 RGD 肽-P-gp 抑制剂
偶联物靶向逆转乳腺癌多药耐药研究
- 批准号:Q24H300033
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
HA/CD44 对 P-gp 介导的狼疮肾炎小鼠激素耐
药的影响及三七皂苷干预的研究
- 批准号:TGY24H290013
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
共有人P-gp同源蛋白的五条真菌基因簇异源表达产物逆转耐药三阴乳腺癌探究
- 批准号:22377105
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
肾病综合征P-gp动态变化介导雷公藤肾脏“效-毒”转化的物质基础及机制研究
- 批准号:82374138
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于超滤质谱分子网络的大戟属植物中新型大环二萜P-gp抑制剂的发现及其对肿瘤药物体内行为影响的研究
- 批准号:82360692
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
基于氟喹诺酮类药物介导肠道菌群下调肠道P-gp的PBPK模型探究达比加群酯给药策略
- 批准号:82304610
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
新型肝素纳米药物通过乙酰肝素酶下调P-gp逆转卵巢癌铂耐药的研究
- 批准号:82303845
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于NF-κB炎症信号通路对P-gp/OAT2的调控探究心脏瓣膜置换术后华法林响应增强的机制
- 批准号:82260729
- 批准年份:2022
- 资助金额:34 万元
- 项目类别:地区科学基金项目
新型苯基呋喃类P-gp抑制剂-叶酸缀合物的设计合成及靶向逆转乳腺癌多药耐药活性研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Investigating the molecular mechanism of P-gp/NHERF-1 network at feto maternal interface and role of paracrine signaling of EVs containing drug transporter proteins
研究胎儿母体界面P-gp/NHERF-1网络的分子机制以及含有药物转运蛋白的EV的旁分泌信号传导的作用
- 批准号:
10748250 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Organic Anion Transporting Polypeptide (OATP), P-glycoprotein (P-gp), and Breast Cancer Resistance Protein (BCRP) transporters modulate tamoxifen response during breast cancer therapy
有机阴离子转运多肽 (OATP)、P-糖蛋白 (P-gp) 和乳腺癌抗性蛋白 (BCRP) 转运蛋白在乳腺癌治疗期间调节他莫昔芬反应
- 批准号:
452037 - 财政年份:2021
- 资助金额:
$ 2.24万 - 项目类别:
Operating Grants
Investigation into the basis of protein-lipid interactions for ATP-Binding Cassette (ABC) transporters BmrA and P-gp, using novel polymer-based solubi
使用新型聚合物溶液研究 ATP 结合盒 (ABC) 转运蛋白 BmrA 和 P-gp 的蛋白质-脂质相互作用的基础
- 批准号:
2431510 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
Studentship
A novel strategy to overcome the P-gp/BCRP drug efflux system at the blood-brain barrier to improve brain uptake of CNS therapeutics
克服血脑屏障处的 P-gp/BCRP 药物流出系统以改善中枢神经系统治疗药物的大脑摄取的新策略
- 批准号:
10225435 - 财政年份:2018
- 资助金额:
$ 2.24万 - 项目类别:
A novel strategy to overcome the P-gp/BCRP drug efflux system at the blood-brain barrier to improve brain uptake of CNS therapeutics
克服血脑屏障处的 P-gp/BCRP 药物流出系统以改善中枢神经系统治疗药物的大脑摄取的新策略
- 批准号:
9761586 - 财政年份:2018
- 资助金额:
$ 2.24万 - 项目类别:
A novel strategy to overcome the P-gp/BCRP drug efflux system at the blood-brain barrier to improve brain uptake of CNS therapeutics
克服血脑屏障处的 P-gp/BCRP 药物流出系统以改善中枢神经系统治疗药物的大脑摄取的新策略
- 批准号:
10452766 - 财政年份:2018
- 资助金额:
$ 2.24万 - 项目类别:
Investigation of the mechanism and its suppression method of organ-specific increase in P-gp activity induced by bitter taste of anticancer drug
抗癌药物苦味引起器官特异性P-gp活性升高的机制及其抑制方法研究
- 批准号:
16K18956 - 财政年份:2016
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The role of miR-27a in regulation of P-gp expression
miR-27a在调节P-gp表达中的作用
- 批准号:
25670078 - 财政年份:2013
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
EFFECT OF BITTER MELON LEAF EXTRACT ON MDR1 GENE EXPRESSION AND FUNCTION OF P-GP
苦瓜叶提取物对MDR1基因表达及P-GP功能的影响
- 批准号:
8359652 - 财政年份:2011
- 资助金额:
$ 2.24万 - 项目类别:
Localized modulation of RPE P-gp/MRP activity for back-of-the-eye drug delivery
局部调节 RPE P-gp/MRP 活性以实现眼后药物输送
- 批准号:
7297149 - 财政年份:2007
- 资助金额:
$ 2.24万 - 项目类别: